Perivascular orientation of astrocytic plaques and tuft-shaped astrocytes

2011 ◽  
Vol 1404 ◽  
pp. 50-54 ◽  
Author(s):  
Katsuhiko Shibuya ◽  
Saburo Yagishita ◽  
Ayako Nakamura ◽  
Toshiki Uchihara
Keyword(s):  
Astrocytic Plaques

scholarly journals MAPT p.V363I mutation

2019 ◽  
Vol 5 (4) ◽  
pp. e347 ◽  
Author(s):  
Sarah Ahmed ◽  
Monica Diez Fairen ◽  
Marya S. Sabir ◽  
Pau Pastor ◽  
Jinhui Ding ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Genetic Analysis ◽  
Corticobasal Degeneration ◽  
Healthy Controls ◽  
Genetic Etiology ◽  
Genotyping Array ◽  
Rare Mutation ◽  
Protein Tau ◽  
Microtubule Binding Domain ◽  
Astrocytic Plaques

ObjectivePatients with corticobasal syndrome (CBS) present with heterogeneous clinical features, including asymmetric parkinsonism, dyspraxia, aphasia, and cognitive impairment; to better understand the genetic etiology of this rare disease, we undertook a genetic analysis of microtubule-associated protein tau (MAPT).MethodsWe performed a genetic evaluation of MAPT mutations in 826 neurologically healthy controls and 173 cases with CBS using the Illumina NeuroChip genotyping array.ResultsWe identified 2 patients with CBS heterozygous for a rare mutation in MAPT (p.V363I) that is located in the highly conserved microtubule-binding domain. One patient was pathologically confirmed and demonstrated extensive 4-repeat-tau-positive thread pathology, achromatic neurons, and astrocytic plaques consistent with corticobasal degeneration (CBD).ConclusionsWe report 2 CBS cases carrying the rare p.V363I MAPT mutation, one of which was pathologically confirmed as CBD. Our findings support the notion that this rare coding change is pathogenic.

Distribution of astrocytic plaques in the corticobasal degeneration brain and comparison with tuft-shaped astrocytes in the progressive supranuclear palsy brain

2003 ◽  
Vol 106 (2) ◽  
pp. 143-149 ◽  
Author(s):  
Manabu Hattori ◽  
Yoshio Hashizume ◽  
Mari Yoshida ◽  
Yasushi Iwasaki ◽  
Nozomi Hishikawa ◽  
...  
Keyword(s):  
Progressive Supranuclear Palsy ◽  
Corticobasal Degeneration ◽  
Astrocytic Plaques

scholarly journals Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology

2021 ◽  
Author(s):  
Shunsuke Koga ◽  
Xiaolai Zhou ◽  
Aya Murakami ◽  
Cristhoper Fernandez De Castro ◽  
Matthew C Baker ◽  
...  
Keyword(s):  
Basal Forebrain ◽  
Frontotemporal Lobar Degeneration ◽  
Disease Process ◽  
Corticobasal Degeneration ◽  
Tau Pathology ◽  
Age Related ◽  
Argyrophilic Grain ◽  
C9orf72 Mutation ◽  
Astrocytic Plaques ◽  
Concurrent Disease

Aims: Accumulating evidence suggests that patients with frontotemporal lobar degeneration (FTLD) can have pathologic accumulation of multiple proteins, including tau and TDP-43. This study aimed to determine the frequency and characteristics of concurrent tau pathology in FTLD with TDP-43 pathology (FTLD-TDP). Methods: The study included 146 autopsy-confirmed cases of FTLD-TDP and 55 cases of FTLD-TDP with motor neuron disease (FTLD-MND). Sections from the basal forebrain were screened for tau pathology with phospho-tau immunohistochemistry. For cases with tau pathology on the screening section, additional brain sections were studied to establish a diagnosis. Genetic analysis of C9ORF72, GRN, and MAPT was performed on select cases. Results: Among 201 cases, we found 72 cases (36%) with primary age-related tauopathy (PART), 85 (42%) with aging-related tau astrogliopathy (ARTAG), 45 (22%) with argyrophilic grain disease (AGD), and 2 cases (1%) with corticobasal degeneration (CBD). Patients with ARTAG or AGD were significantly older than those without these comorbidities. One of the patients with FTLD-TDP and CBD had C9ORF72 mutation and relatively mild tau pathology, consistent with incidental CBD. Conclusion: The coexistence of TDP-43 and tau pathologies was relatively common, particularly PART and ARTAG. Although rare, individual patients with FTLD can have multiple concurrent proteinopathies. The absence of TDP-43-positive astrocytic plaques may suggest that CBD and FTLD-TDP were independent disease processes in the two patients with both tau and TDP-43 pathologies. It remains to be determined if mixed cases represent a unique disease process or two concurrent disease processes in an individual.

scholarly journals Astrogliopathy in Tauopathies

Neuroglia ◽  
2018 ◽  
Vol 1 (1) ◽  
pp. 126-150 ◽  
Author(s):  
Isidro Ferrer
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Glial Cells ◽  
Neuronal Damage ◽  
Pathological Process ◽  
Loss Of Function ◽  
System Integrity ◽  
The Central Nervous System ◽  
Astrocytic Plaques ◽  
Complex Scenario

Astrocytes are involved in many diseases of the central nervous system, not only as reactive cells to neuronal damage but also as primary actors in the pathological process. Astrogliopathy is a term used to designate the involvement of astrocytes as key elements in the pathogenesis and pathology of diseases and injuries of the central nervous system. Astrocytopathy is utilized to name non-reactive astrogliosis covering hypertrophy, atrophy and astroglial degeneration with loss of function in astrocytes and pathological remodeling, as well as senescent changes. Astrogliopathy and astrocytopathy are hallmarks of tauopathies—neurodegenerative diseases with abnormal hyper-phosphorylated tau aggregates in neurons and glial cells. The involvement of astrocytes covers different disease-specific types such as tufted astrocytes, astrocytic plaques, thorn-shaped astrocytes, granular/fuzzy astrocytes, ramified astrocytes and astrocytes with globular inclusions, as well as others which are unnamed but not uncommon in familial frontotemporal degeneration linked to mutations in the tau gene. Knowledge of molecular differences among tau-containing astrocytes is only beginning, and their distinct functional implications remain rather poorly understood. However, tau-containing astrocytes in certain conditions have deleterious effects on neuronal function and nervous system integrity. Moreover, recent studies have shown that tau-containing astrocytes obtained from human brain tauopathies have a capacity for abnormal tau seeding and spreading in wild type mice. Inclusive conceptions include a complex scenario involving neurons, glial cells and local environmental factors that potentiate each other and promote disease progression in tauopathies.

scholarly journals Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Rebecca R. Valentino ◽  
Nikoleta Tamvaka ◽  
Michael G. Heckman ◽  
Patrick W. Johnson ◽  
Alexandra I. Soto-Beasley ◽  
...  
Keyword(s):  
Progressive Supranuclear Palsy ◽  
Multiple Testing ◽  
Corticobasal Degeneration ◽  
Genomic Variation ◽  
Tau Pathology ◽  
Mtdna Haplogroups ◽  
Astrocytic Plaques ◽  
Mitochondrial Phylogeny ◽  
Control Study ◽  
Unique Snps

Abstract Mitochondrial health is important in ageing and dysfunctional oxidative phosphorylation (OXPHOS) accelerates ageing and influences neurodegeneration. Mitochondrial DNA (mtDNA) codes for vital OXPHOS subunits and mtDNA background has been associated with neurodegeneration; however, no study has characterised mtDNA variation in Progressive supranuclear palsy (PSP) or Corticobasal degeneration (CBD) risk or pathogenesis. In this case–control study, 910 (42.6% male) neurologically-healthy controls, 1042 (54.1% male) pathologically-confirmed PSP cases, and 171 (52.0% male) pathologically-confirmed CBD cases were assessed to determine how stable mtDNA polymorphisms, in the form of mtDNA haplogroups, were associated with risk of PSP, risk of CBD, age of PSP onset, PSP disease duration, and neuropathological tau pathology measures for neurofibrillary tangles (NFT), neuropil threads (NT), tufted astrocytes (TA), astrocytic plaques (AP), and oligodendroglial coiled bodies (CB). 764 PSP cases and 150 CBD cases had quantitative tau pathology scores. mtDNA was genotyped for 39 unique SNPs using Agena Bioscience iPlex technologies and mitochondrial haplogroups were defined to mitochondrial phylogeny. After adjustment for multiple testing, we observed an association with risk of CBD for mtDNA sub-haplogroup H4 (OR = 4.51, P = 0.001) and the HV/HV0a haplogroup was associated with a decreased severity of NT tau pathology in PSP cases (P = 0.0023). Our study reports that mitochondrial genomic background may be associated with risk of CBD and may be influencing tau pathology measures in PSP. Replication of these findings will be important.

scholarly journals TAU-IMMUNOHISTOCHEMICAL AND -IMMUNOELECTRON MICROSCOPICAL INVESTIGATION OF ASTROCYTIC PLAQUES IN PROGRESSIVE SUPRANUCLEAR PALSY

1997 ◽  
Vol 18 (2) ◽  
pp. 145-148 ◽  
Author(s):  
EIZO ISEKI ◽  
FENG LI ◽  
KENJI KOSAKA ◽  
TORU NISHIMURA ◽  
HARUHIKO AKIYAMA ◽  
...  
Keyword(s):  
Microscopical Investigation ◽  
Astrocytic Plaques

Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy

1998 ◽  
Vol 96 (4) ◽  
pp. 401-408 ◽  
Author(s):  
T. Komori ◽  
N. Arai ◽  
M. Oda ◽  
H. Nakayama ◽  
H. Mori ◽  
...  
Keyword(s):  
Progressive Supranuclear Palsy ◽  
Corticobasal Degeneration ◽  
Astrocytic Plaques

scholarly journals Deep Learning-Based Image Classification in Differentiating Tufted Astrocytes, Astrocytic Plaques, and Neuritic Plaques

2021 ◽  
Author(s):  
Shunsuke Koga ◽  
Nikhil B Ghayal ◽  
Dennis W Dickson
Keyword(s):  
Deep Learning ◽  
Image Classification ◽  
Cross Validation ◽  
Corticobasal Degeneration ◽  
Classification Model ◽  
Neuritic Plaques ◽  
Tissue Sections ◽  
Learning Platform ◽  
Lesion Type ◽  
Astrocytic Plaques

Abstract This study aimed to develop a deep learning-based image classification model that can differentiate tufted astrocytes (TA), astrocytic plaques (AP), and neuritic plaques (NP) based on images of tissue sections stained with phospho-tau immunohistochemistry. Phospho-tau-immunostained slides from the motor cortex were scanned at 20× magnification. An automated deep learning platform, Google AutoML, was used to create a model for distinguishing TA in progressive supranuclear palsy (PSP) from AP in corticobasal degeneration (CBD) and NP in Alzheimer disease (AD). A total of 1500 images of representative tau lesions were captured from 35 PSP, 27 CBD, and 33 AD patients. Of those, 1332 images were used for training, and 168 images for cross-validation. We tested the model using 100 additional test images taken from 20 patients of each disease. In cross-validation, precision and recall for each individual lesion type were 100% and 98.0% for TA, 98.5% and 98.5% for AP, and 98.0% and 100% for NP, respectively. In a test set, all images of TA and NP were correctly predicted. Only eleven images of AP were predicted to be TA or NP. Our data indicate the potential usefulness of deep learning-based image classification methods to assist in differential diagnosis of tauopathies.

Sign in / Sign up

Export Citation Format

Share Document